Clinical Trial Details
— Status: Enrolling by invitation
Administrative data
| NCT number |
NCT05444361 |
| Other study ID # |
CRYO for Mastectomy (DoD) |
| Secondary ID |
|
| Status |
Enrolling by invitation |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
September 15, 2022 |
| Est. completion date |
May 14, 2027 |
Study information
| Verified date |
May 2024 |
| Source |
University of California, San Diego |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Breast cancer is the most common type of cancer in women. Removal of the breast, called
"mastectomy", is performed either when there is cancer-or an increased risk of cancer-in the
breast. This can result in a lot of pain during the months after surgery.
Opioids-"narcotics"-are the most common pain control method provided to patients; but they
frequently do not relieve enough pain, have undesirable side effects like vomiting and
constipation, and are sometimes misused which can lead to addiction. Mastectomy also
frequently results in long-term pain which can interfere with physical and emotional
functioning; and the more pain patients have immediately after surgery, the greater the risk
of developing long-term pain. Numbing the nerves with local anesthetic can decrease the
amount of short- and long-term pain experienced by patients, but even the longest types of
these nerve blocks last for hours or days, and not the 1-2 months of pain typically following
mastectomy. So, there is reason to believe that if the nerve blocks could be extended so that
they last longer than the pain from surgery, short- and long-term pain might be avoided
completely without the need for opioids. A prolonged nerve block may be provided by freezing
the nerve using a technique called "cryoneurolysis". With cryoneurolysis and ultrasound
machines, a small needle-like "probe" may be placed through anesthetized skin and guided to
the target nerve to allow freezing. The procedure takes about 5 minutes for each nerve,
involves little discomfort, has no side effects, and cannot be misused or become addictive.
After 2-3 months, the nerve returns to normal functioning. The investigators have completed a
small study suggesting that a single cryoneurolysis treatment may provide potent pain relief
after mastectomy. The ultimate objectives of the proposed research study are to determine if
temporarily freezing the nerves that go to the breast will decrease short-term pain, opioid
use, physical and emotional dysfunction, and long-term pain following mastectomy when added
to current and customary postoperative analgesics.
The current project is a pragmatic, multicenter, randomized, triple-masked (investigators,
participants, statisticians), sham/placebo-controlled, parallel-arm, human-subjects,
post-market clinical trial to determine if cryoneurolysis is an effective non-opioid
treatment for pain following mastectomy.
Description:
All participants will continue to receive standard and customary postoperative analgesics of
their local treatment center, so there is no risk of participants receiving a lower degree of
analgesia than if they otherwise did not enroll in the study. The cryoneurolysis procedure
will be done in addition to standard local institutional standard analgesic treatments.
The investigators propose a pragmatic, multicenter, randomized, triple-masked (investigators,
participants, statisticians), sham/placebo-controlled, parallel-arm, human-subjects clinical
trial to determine if cryoneurolysis is an effective non-opioid treatment for pain following
mastectomy. Participants will be individuals undergoing unilateral or bilateral mastectomy,
recruited at 6 centers:
- Walter Reed National Military Medical Center, Bethesda, Maryland
- U.C. San Diego, San Diego, California
- University of Florida, Gainesville, Florida
- Cedars-Sinai, Los Angeles, California
- Cleveland Clinic, Cleveland, Ohio
For women of childbearing age with the possibility of pregnancy, a sample of urine will be
collected before any study interventions to confirm a non-pregnant state. Participants will
have a peripheral intravenous (IV) catheter inserted, standard noninvasive monitors applied
(blood pressure cuff, pulse oximeter, 5-lead ECG), and oxygen administered via a facemask.
Midazolam and fentanyl (IV) will be titrated for patient comfort as needed throughout the
procedure, while ensuring that patients remain responsive to verbal cues.
Peripheral nerve block. Not all enrolling centers provide peripheral blocks as part of their
standard-of-care. Due to the pragmatic design of this trial, study participation will not
alter an institution's current practice. If the local practice includes a postoperative
continuous peripheral nerve block, a perineural catheter will be inserted 2-5 cm beyond the
needle tip, the needle withdrawn over the catheter, the catheter affixed with an occlusive
sterile dressing.
Participants will be allocated to one of two treatments:
1. cryoneurolysis
2. sham cryoneurolysis (placebo control)
Randomization will be stratified by enrolling institution, surgical site (unilateral vs.
bilateral), and axillary involvement (none/biopsy vs. dissection) in a 1:1 ratio, and in
randomly chosen block sizes. Randomization lists will be created using Statistical Analysis
Software computer-generated tables by the informatics division of the Department of Outcomes
Research (Cleveland Clinic, Cleveland, OH). Treatment group assignment will be conveyed to
the enrolling sites via the same secure web-based system (REDCap) used to collect and collate
all post-intervention endpoints.
There are multiple types of cryoneurolysis machines cleared by the US FDA, all of which work
on the same principle of a gas being passed through a small annulus, resulting in a dramatic
pressure drop and accompanying temperature drop due to the Joule-Thomson effect. This study
will utilize two different consoles [second option added May 8, 2023]: the Epimed
International (Farmers Branch, TX) and Varian Medical Systems (Palo Alto, CA) machines. Which
machine is used is determined simply by the machine that each enrolling center has at its
disposal.
Varian: This machine uses argon for the freeze cycle and helium to help decrease the thaw
period duration. Sham probes are not available for this type of machine, and therefore an
active probe will be used for all participants. For participants randomized to active
treatment, the probe will be connected to the machine as usual, the argon (and helium) passed
through the probe and then back into the machine, and finally vented out from the console.
For participants randomized to sham treatment, the probe will be connected to an inactive
connector on the back of the machine. For these participants the gas will simply be ejected
directly from the console without ever having passed through the probe. The investigator
administering the study intervention will access the treatment group assignment using the
secure web-based system and attach the probe (active) or leave the tubing end close to the
machine (sham). Therefore, all investigators, participants, and clinical staff will be masked
to treatment group assignment, with the only exception being the unmasked individual who
performs the procedure (and will not have subsequent contact with the participant).
Epimed: This machine uses nitrous oxide for the freeze cycle with a passive thaw (no gas
flow). Cryoneurolysis probes are available that either (1) pass nitrous oxide to the distal
end inducing freezing temperatures; or (2) vent the nitrous oxide at the proximal end of the
probe so that no gas reaches the distal end, resulting in no temperature change. The latter
is a sham procedure since without the temperature change, no ice ball forms and therefore the
target nerve is not affected. Importantly, these probes are indistinguishable in appearance
and will be differentiated only by an identifying stamp on the underside of the connector
which is not visible during use.
The investigator administering the study intervention will access the treatment group
assignment using the secure web-based system and attach the appropriate probe to the
cryoneurolysis device. Therefore, all investigators, participants, and clinical staff will be
masked to treatment group assignment, with the only exception being the unmasked individual
who performs the procedure (and will not have subsequent contact with the participant). For
both types of machines, it is impossible to mask the individual performing the cryoneurolysis
procedure because the ice ball forming at the distal end of the probe-with active
treatment-is clearly visible by ultrasound; and the lack of an ice ball for placebo
participants is equally clear. It is essential to continuously visualize the probe and target
nerve throughout the freeze/thaw cycle(s) to ensure the entire nerve diameter is adequately
treated and remains relatively motionless. This cannot be achieved if the ultrasound is
turned off during gas administration in an attempt to mask the provider.
Study intervention. The 2nd-6th thoracic intercostal nerves will be treated on the
ipsilateral surgical side (bilaterally for bilateral surgical procedures). Using a
curved-array transducer, the intercostal nerve will be visualized using ultrasound just
inferior to each treated rib immediately distal to the costotransverse joint. For
participants without a paravertebral block, a skin wheal of lidocaine 1% will be raised
immediately inferior to the transducer to anesthetize the skin. An IV-like hollow-bore
introducer may be inserted through the skin and guided to the target nerve--this is based on
operator personal preference. For participants without anesthetized intercostal nerves from a
peripheral nerve block, lidocaine 1.5-2.0% 2 mL may be injected through the introducer prior
to the cryoneurolysis probe introduction to provide anesthesia during the cryoneurolysis
cycles, although this is not universally applied (they cryoneurolysis treatment itself
induces anesthesia).
A portable cryoneurolysis device (Varian CryoCare or Epimed PainBlocker) will be used. The
probe will be inserted adjacent to the intercostal nerve.
Varian: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon
activation (2000 psi and 100% power) followed by a 30-second helium defrost.
Epimed: The cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation
(active or sham) separated by a 1-minute defrost.
The introducer and probe will be withdrawn and this process repeated for each additional
intercostal nerve to be treated. For bilateral mastectomies, the study intervention will be
repeated on the contralateral side with the same probe.
Intraoperative course. Due to the pragmatic nature of this trial, the investigators aim to
change each center's standard practice as little as possible and rather investigate the
results of adding the intervention to current practice. The investigators will therefore
record intraoperative factors such as type of general anesthetic, axillary dissection, opioid
administration, and local anesthetic supplementation; however, the investigators will not
require changes to current standard practice.
Postoperative course. Standard local supplemental analgesics will be used due to the
pragmatic design of this trial. For analysis purposes, all opioids will be converted to oral
oxycodone equivalents. Following a cryoneurolysis treatment, no action is required by
patients regarding this intervention. For example, in contrast to epidural infusions, there
is no infusion pump to manage or anesthetic fluid to replenish. At enrolling centers that
provide a postoperative continuous peripheral nerve block, the ropivacaine or bupivacaine
infusions will be administered per local protocol with the catheters removed on postoperative
day 1 or 2 prior to hospital discharge.
Following study completion, the results will be mailed electronically or by the United States
Postal Service to all enrolled participants in written form using non-technical (e.g.,
"layperson") language.
Outcome Measurements (End Points). The investigators have selected outcome measures that have
established reliability and validity, with minimal inter-rater discordance, and are
recommended for pain-related clinical trials by the World Health Organization and the
Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT)
consensus statement (Table 1, below).5 End points will be evaluated at baseline (prior to
surgery on postoperative day 0), as well as postoperative days 1, 2, 3, 4, 7, 21, 30, 45; and
months 2, 3, 6, 9 and 12).
Statistical Plan and Data Analysis
Primary Specific Aim: To determine the effect of cryoneurolysis on postoperative opioid
requirements and analgesia following mastectomy.
Hypothesis 1: Opioid consumption will be significantly decreased in the first two months
following surgery with cryoneurolysis compared with usual and customary analgesia.
Hypothesis 2: Surgical pain will be significantly decreased within the first two months
following surgery with cryoneurolysis compared with usual and customary analgesia (measured
with a Numeric Rating Scale).
Primary end point: In order to claim that cryoneurolysis is superior to usual and customary
analgesia, at least one of Hypotheses 1 and 2 above must be superior while the other at least
noninferior.
Secondary Specific Aims: To determine the effect of cryoneurolysis on physical and emotional
functioning and chronic pain following mastectomy.
Hypothesis 3: Physical and emotional functioning will be significantly improved within the
first two months following surgery with cryoneurolysis as compared with usual and customary
analgesia (measured with the Interference Domain of the Brief Pain Inventory).
Hypothesis 4: The incidence of chronic pain will be significantly decreased 6 and 12 months
following surgery with cryoneurolysis as compared with usual and customary analgesia.
Hypothesis 5: The intensity of chronic pain will be significantly decreased 6 and 12 months
following surgery with cryoneurolysis as compared with usual and customary analgesia
(measured with a Numeric Rating Scale).
Balance on baseline covariates will be assessed using absolute standardized difference
(ASD):50 i.e., difference in means or proportions divided by the standard deviation. ASD >
0.1 will be considered to indicate imbalance, and these variables will be adjusted for in the
statistical analyses. Analyses will be carried out using modified intention-to-treat (i.e.,
patients who received any study treatment will be analyzed according to the group to which
they were randomized). The overall type I error rate of the study will be controlled using a
parallel gatekeeping procedure (see Study-wide Type I error rate control).
Primary Objective (Hypotheses 1 and 2). The investigators will estimate the treatment effect
of cryoneurolysis on opioid consumption (Hypothesis 1) and average pain score (Hypothesis 2)
using a joint hypothesis-testing framework. The investigators will conclude that
cryoneurolysis is more effective compared to the standard of care if it is noninferior on
both opioid consumption and pain score, and superior for at least one of the outcomes during
the first 2 months after surgery. No adjustment for multiple testing is needed for
noninferiority testing since the investigators require noninferiority on both pain score and
opioid consumption outcomes.
Noninferiority Testing.
Hypothesis 1 (Opioid consumption). Cumulative opioid assumption is typically log-normally
distributed. The investigators will therefore assess the treatment effect on the
log-transformed cumulative opioid consumption at 2 months using a linear regression model.
The investigators will test for NI of cryoneurolysis to standard of care using a 1-tailed
test assuming alpha of 0.025 and NI delta of 1.2 for the ratio of geometric means
(treatment/placebo). All opioids will be converted to oral oxycodone equivalents.
Hypothesis 2 (Average pain score). The investigators will test for noninferiority (NI) of
cryoneurolysis to standard of care using 1-tailed tests and assuming a 1-tailed alpha of
0.025. The primary pain outcome will be the area under the curve (AUC) of patient "average"
pain scores over the first 2 months (60 days; AUC-60). For this outcome the noninferiority
(NI) delta will be a ratio of geometric means of 1.2 in the AUC-60. Since AUC-60 is expected
to be skewed and to have some proportion of zero values, the investigators will estimate the
treatment effect a 2-sample t-test on the log-transformed (AUC-60 + 1). Noninferiority will
be concluded if the upper 95% confidence interval of the ratio of geometric means is below
the NI delta.
Superiority Testing. If NI is found on both pain and opioid use, the investigators will test
for superiority on each of cumulative opioid consumption and average pain AUC-60 using
1-tailed tests (using the primary analyses specified above) with overall 1-tailed alpha of
0.025. Since there are 2 tests for superiority the investigators will apply a Holm-Bonferroni
correction and use a significance criterion of 0.025/2 for the smaller P-value and 0.025 for
the larger. Similar tests will be conducted for the sensitivity analyses for pain score.
Cryoneurolysis will be concluded more effective at pain management than standard care, and
the joint null hypothesis rejected, if found superior on at least pain score or opioid
consumption and at least noninferior on both.
Secondary pain outcomes in first 60 days. For each of average, current, least and worst pain
score, as well as the pain with ipsilateral arm raise, the investigators will conduct all of
the analyses describe above for average pain score, as well as 1) assessing the
treatment-by-time interaction in a linear mixed effects model using all measurements over
time, and 2) estimating and reporting the treatment effect at each time point while
controlling type I error across time points within each outcome variable using the
Holm-Bonferroni procedure.
Sensitivity analyses for average pain score methodology. In addition to analyzing the AUC,
the investigators will assess the treatment effect on patient "average" pain scores over time
using a linear mixed effects model assuming an autoregressive (AR[1]) correlation structure
across scores for the same individual over time. Factors will be intervention, time
(categorical) and baseline average pain score. The investigators will then test for
noninferiority with a 1-tailed t-test in which the numerator is the estimated treatment
effect minus the NI delta of 1 point and the denominator is the standard error of the
estimated treatment effect. In another sensitivity analysis, the investigators will use a
mixed effects proportional odds model with an autoregressive correlation structure to assess
the treatment effect on pain score as an ordinal outcome.
Hypothesis 3 (Physical and emotional functioning). Physical and emotional functioning of
patients will be assessed using: 1) the interference domain of the Brief Pain Inventory
(BPI), and 2) the Patient Health Questionnaire (PHQ-2). For the BPI Interference subscale,
the effect of the intervention will be assessed over the first 2 months as in Hypotheses 2
and 3 -- using patient AUC as primary analysis and a linear mixed model adjusting for
baseline BPI-Interference domain score as secondary. The investigators will further analyze
the outcome over the entire first 12 months in a linear mixed effects model and compare the
treatment groups at each time point, controlling type I error as specified in the primary
objective under "Secondary pain outcomes in first 60 days". The effect of the intervention on
depression as assessed by the Patient Health Questionnaire (PHQ-2) at 3-12 months will be
analyzed by Wilcoxon rank-sum tests at each time, with treatment effect estimated as median
difference (95% CI).19,20 In addition, a proportional odds logistic regression analysis
adjusting for clinical site will be conducted for each time point.
Hypotheses 4 and 5 (chronic pain). The effect of the intervention on the maximum/worst pain
(ordinal scale) experienced by patients at each of 6 and 12 months will be assessed by
separate Wilcoxon rank-sum tests at each time point, with treatment effect estimated as
median difference (95% CI). In addition, a proportional odds logistic regression analysis
adjusting for clinical site will be conducted for each time point. Second, the effect of the
intervention on presence of any pain (binary - yes/no) at each of 6 and 12 months will be
assessed using chi-square analyses and relative risk (95% CI), as well as
Cochran-Mantel-Haenszel tests stratified by clinical site.
Study-wide Type I error control. The investigators will use a parallel gatekeeping procedure
to control the study-wide type I error at 0.05. For this procedure the investigators
therefore have prioritized (a priori) the study outcomes into 7 ordered sets (Table 5,
following page). Analysis will proceed in that order, and testing will proceed through each
"gate" to the next set if and only if at least one outcome in the current set reaches
significance. The significance level for each set will be 0.05 times a cumulative penalty for
non-significant results in previous sets (i.e., a "rejection gain factor" equal to the
cumulative product of the proportion of significant tests across the preceding sets). Within
a set, a multiple comparison procedure (Holm-Bonferroni correction) will be used as needed to
control the type I error at the appropriate level. Although the first set represents the
1-tailed joint hypothesis tests for noninferiority and superiority at alpha=0.025, without
modifying the joint hypothesis test the investigators will use the corresponding 2-tailed
alpha level of 0.05 for the gatekeeping, as all other sets involve 2-tailed tests. Some of
the outcomes listed in the gatekeeping table are overall assessments over repeated measures.
As detailed in statistical methods, treatment effects may also be assessed at individual time
points. Such assessments will proceed according to the gatekeeping framework such that 1)
type I error will be controlled across repeated measurements, and 2) inference will not be
made on outcome variables that are excluded from formal testing/inference due to the
gatekeeping results.
Parallel gatekeeping procedure [revised December 12, 2022, after 7 participants were enrolled
because the study is a pragmatic trial and not all enrolling centers include peripheral nerve
blocks and/or perineurial local anesthetic infusions as part of their standard care; and
therefore anticipated opioid consumption and pain scores will be higher across all groups
relative to the single-center pilot study]
Sets: Time frame... Required to pass to next set
1. H1/H2 - Joint hypothesis - opioids and pain Requires: NI both, superiority on at least
one, 2 months, Reject joint H0 (1 joint test)
2. H3 - BPI interference subscale, 2 months, Significance on this outcome
3. H4/H5 - Chronic pain: (1) incidence and (2) worst pain, 6 months, Significance on either
outcome H4/H5
4. H4/H5 - Chronic pain: (1) incidence and (2) worst pain, 12 months, Significance on
either outcome H4/H5
5. H2 - Percentage of each group that required <=3 opioid tablets from recovery room
discharge through 2 mos
6. H1 - Percentage of each group that experienced no more than moderate (NRS < 7) pain at
all time points 2 months, Significance on either outcome 5 or 6
7. H3 - Depression screen PHQ-2 6 & 12 months Significance on either outcome
Interim Analyses. The investigators will use a group sequential design with a non-binding
futility boundary and conduct an interim analysis at 50% of the maximum planned enrollment to
assess the efficacy/futility of the intervention. Specifically, the investigators will
maintain the overall alpha level (monitoring efficacy) at 0.025 using gamma parameter of -4
and power at 90% (monitoring beta, type II error) using gamma parameter of -4. Under the
alternative hypothesis, the cumulative probability of crossing an efficacy (and futility in
parentheses) boundary at the 1st and 2nd analyses will be 0.33 (0.01), and 0.90 (0.10). Under
the joint hypothesis testing framework, the investigators aim to have 90% power to detect NI
on both outcomes and superiority on any one outcome.
Sample Size Justification and Power Analyses. Sample size calculations and power analyses for
the full study were informed by estimates from the pilot trial. The investigators plan to
have 90% power for rejecting the joint hypothesis test for the primary aim.
Opioids. In the pilot study (N=30), the median [quartiles] of cumulative opioid consumption
over 60 days was 91 [15, 146] in the control group and 3 [0, 15] in the treatment group. The
ratio of geometric means [95% CI] was 0.13 [0.03, 0.54] indicating an 87% estimated relative
percent reduction in cumulative opioid consumption at 60 days. The investigators observed a
coefficient of variation (CV) of 1.4. Noninferiority: Assuming a geometric mean ratio of
0.70, a NI delta of 1.2, alpha of 0.025 and CV of 1.4, the investigators would have 96.2%
power to reject the null hypothesis. Superiority: A sample size of 108 patients in each group
would yield 95.0% power to detect a geometric mean ratio of 0.57 (treatment/ placebo),
assuming a CV of 1.4, a 1-tailed alpha of 0.0125, and after adjusting for interim analyses.
Pain. In the pilot study (N=30), the median [quartiles] of AUC-60 was 29 [16, 67] in the
control group and 1 [0, 4] in the treatment group. The ratio of geometric means [95% CI] was
0.10 [0.04, 0.27] indicating a 90% estimated relative percent reduction in pain score at 60
days in treatment versus placebo. The investigators observed a coefficient of variation (CV)
of 1.4. Noninferiority: Assuming a true ratio of geometric means in AUC-60 of 0.71, a NI
delta of 1.2, a 1-tailed alpha of 0.025 and CV of 1.4, a sample size of 108 patients per
group would yield 95.3% power to detect noninferiority of cryoanalgesia versus control after
adjusting for interim analyses. Superiority: A sample size of 108 patients in each group
would yield 95.0% power to detect a geometric mean ratio of 0.57 (treatment/placebo),
assuming a CV of 1.4, a 1-tailed alpha of 0.0125, and after adjusting for interim analyses.
With the same sample size, the investigators would have 92.4% power to detect a decrease of 1
point in the pain score assuming alpha = 0.0125, standard deviation of 2.5, intraclass
correlation coefficient (ICC) of 0.55 and an average cluster size (measurements per
participant) of 7.
Power for Joint Hypothesis test. The investigators will have 90% power to reject the joint
null hypothesis, e.g., 95% power for superiority on pain score times 96% power for
noninferiority on opioids = 91%, assuming independence between the two outcomes.
Loss to follow-up. Within our pilot study (n=30) there were no lost patients for the full
1-year follow-up period. However, this might be a unique subset of patients which may differ
from a future cohort at the same or other enrolling centers. Based on previous multicenter
clinical trials, the investigators estimate that at most 7% of participants in each group are
expected to drop out of the study before reaching the 2-months primary outcome assessment.
For those missing data the investigators will use intent-to-treat and multiple imputation
(multiple imputation for chained equations (MICE)) using data on all observed baseline and
outcome data.
Sample size re-estimation. At the first interim analysis (50% of maximum enrollment), the
investigators will estimate variance and ICC of the pain scores, and CV for opioids, and
re-estimate the required sample size. All analyses will either adjust for clinical site
(e.g., in a regression model) or consider it as a stratification variable (e.g., in a
Cochran-Mantel-Haenszel relative risk analysis). Statistical Analytic Software (Carey, North
Carolina), R programming language (The R Project for Statistical Computing) and East 5.3
software (Cytel Inc.) will be used for all analyses.
